European Leukemia Trial Registry
Trial: CML AMN107 2303

More Details
Title Imatinib vs. Nilotinib in newly diagnosed (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)
Scientific Title A Phase III Multi-Center, Open-Label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Short Title CML AMN107 2303
Trialgroup NN
Type of Trial multicentric, randomized, open-label
Disease Chronic myeloid leukemia(CML) Chronic Phase
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.05.2007
Leader Ottmann, Prof. Dr., Oliver
Contactperson

principal investigator
Ottmann, Prof. Dr., Oliver
Tel: +49 (0)69 6301 87070
Fax: +49 (0)69 6301 4170
Email: ottmann@em.uni-frankfurt.de

Study Centre
Binckebanck, Anja
Tel: +49 (0)69 6301-6221
Fax: +49 (0)69 6301-7463
Email: binckebanck@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 09.10.2007 Anja Hellenbrecht
changed 13.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org